definiens: . License Income shall mean all amounts received by a Party and/or its Affiliates fromThird Parties in connection with or related to the licensing or sublicensing to such Third Parties of rights toFiclatuzumab, including : ( i ) all upfront fees, milestone payments and royalties ; ( ii ) transfer pricing amounts paid inrespect of Ficlatuzumab supplied to such Third Parties ; ( iii ) investments in securities ; and ( iv ) research andDevelopment funding, but ( notwithstanding the foregoing ) excluding:(a ) transfer pricing amounts equal to such Party ’s and/or its Affiliates ’ Ficlatuzumab Cost of Goods suppliedto such Third Parties;(b ) amounts received by such Party and/or its Affiliates from such Third Parties as the purchase price forsuch Party ’s and/or its Affiliates ’ debt or equity securities at prices not in excess of the then - current market price ofsuch securities or, if such securities are not publicly traded, the then - current fair market value of such securities ; 7EXECUTION VERSION ( c ) amounts received by such Party and/or its Affiliates for future research and Development activitiesundertaken for, or in collaboration with, or other services provided to, such Third Parties at rates not to exceed the fairmarket value of such services, and(d ) amounts received by such Party and/or its Affiliates as reimbursement for costs incurred by such Partyand / or its Affiliates after the grant of the license or sublicense in the performance of such Party ’s and/or its Affiliates’obligations thereunder